NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) and certain officers. The class action, filed in the United States District Court for the Northern District of California and filed at 22-cv-06985, is brought on behalf of a class consisting of all persons and entities other than the defendants who purchased or otherwise acquired Eiger securities March 10, 2021 and October 4, 2022, both dates inclusive (the “Collection Period”), in an attempt to recover damages caused by Defendants’ violations of the federal securities laws and to seek remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder against the Company and certain of its senior officials.

If you are a shareholder who is purchasing or otherwise acquiring Eiger securities, you have until January 9, 2023 to petition the court to appoint you lead plaintiff for the class. A copy of the complaint is available at www.pomerantzlaw.com. To discuss this promotion, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, ext. 7980. Persons inquiring by email are asked to provide their mailing address, telephone number and the number of shares purchased.

[Click here for information about joining the class action]

Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases.

Eiger’s product candidates include peginterferon lambda. Peginterferon Lambda is being evaluated for, Among other thingsthe treatment of COVID-19 in the TOGETHER Study that is an independent, multi-center, investigator-sponsored, randomized, placebo-controlled, adaptive-platform, phase 3 study evaluating multiple therapeutics in newly diagnosed, non-hospitalized, high-risk patients…